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We are delighted to welcome you to the first issue of
Current Controlled Trials in Cardiovascular Medicine.
With this innovative journal, published both on the web
and in print, our aim is to stimulate debate, facilitate com-
munication among investigators and users of trial results,
provide tools, advice, and support for investigators and
users of trial results, and to bring you the best available
information relating to the application of clinical trials to
cardiovascular practice.
Innovative approach
This journal is the first of a family of journals planned by
Current Controlled Trials (a member of the Current
Science Group), each focusing on a different area of med-
icine. All will make full use of the new technology to meet
the needs of clinical investigators and those who use the
results of clinical trials to improve health care. Four innova-
tive features distinguish these journals from most existing
publications. The first is full text open access to reports of
primary research. All primary research reports that we
publish will be made available free, both on our website
(http://cvm.controlled-trials.com) and on BioMed Central
(http://biomedcentral.com), as well as being made imme-
diately available on PubMed Central (http://pubmedcen-
tral.nih.gov), the open access repository of primary
biomedical research set up by the US National Institutes
of Health. This means that authors can be sure that their
work will be fully accessible to researchers and users of
research around the world. 
The second innovation is that authors of primary research
will retain the copyright for their work, which means that
they will be free to circulate their data and articles to others. 
The third innovation is that we have a bias towards rather
than against publication. All trials that are methodologi-
cally and ethically sound will be accepted for publication,
after peer review and appropriate revision, whether their
findings are positive or negative. By doing this, while
maintaining the scientific validity of published reports of
trials, we aim to limit the tendency towards publishing
only positive results of trials and to make the data from
clinical trials more easily accessible for systematic review
and meta-analysis. 
The fourth innovation is that we aim to support trials (and
investigators) from inspiration to publication and beyond.
We will do this in several ways. We will encourage investi-
gators to register their trials within the metaRegister of
Controlled Trials (http://controlled-trials.com) and to apply
for an International Standard Randomised Controlled Trial
Number (ISRCTN), also available at the Current Con-
trolled Trials website (http://controlled-trials.com). Both
initiatives aim to increase the likelihood that trial results will
be published and can be easily accessed by systematic
reviewers and other users of clinical trial results.
We are also following The Lancet’s lead in welcoming
submission of trial protocols [1]. These will be peer
reviewed and posted if accepted. Acceptance represents
a provisional commitment, pending peer review, to publish
the results of the trial should the authors wish to submit
them to us. We are also exploring the possibility that
posting protocols on the Current Science Group’s open
access sites (http://biomedcentral.com and http://con-
trolled-trials.com) will enable investigators to use this as a
channel for recruiting participants, by linking to the
metaRegister and to other open-access sites that provide
information about ongoing trials.
We will provide a home on the web (http://cvm.controlled-
trials.com) for any information or communication that
investigators wish to post relating to their trial. This may
include trial co-ordination messages, information forCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Furberg and Pitt
participants, interim analyses, preliminary data, and full
data sets. And of course, when results are available, we
welcome the submission of full reports of trials. Our
website (http://cvm.controlled-trials.com) also allows rapid
feedback from peers and users, and authors will be able
to post revisions of their published manuscripts in
response to this feedback.
Finally, through the commissioning of reviews and com-
mentaries, we will place trial results in context, by explor-
ing what they add, where they fit into the broader picture,
and what are the implications for future research.
Ensuring quality and integrity
We aim to do everything we can to ensure the quality and
integrity of published information. We therefore welcome
recent developments aimed at improving the reporting of
trials and the ethics of scientific publishing. We will be
asking all authors to ensure that their trial has an ISRCTN
(available at http://controlled-trials.com), to submit their
trial reports in accordance with the CONSORT guidelines
[2], to provide a statement describing what contribution
each of them made to the published article [3], and to
declare any competing interests [4].
In return, we are committed to providing a thorough and
speedy peer review process. We pledge to reach a deci-
sion on all submissions within 6 weeks of receipt, and to
publish articles on line within one month of acceptance —
see our website soon (http://cvm.controlled-trials.com) for a
full description of our peer review and editorial processes,
and now for a list of our international editorial board and
associate editors. Peer reviewers will be asked to declare
competing interests, and, in the light of recent research
[5,6], we will be exploring ways to make the peer review
process more open and accountable. The web allows us to
transform peer review from a one-off assessment to an
ongoing process of feedback and comment. We also hope
to improve the accuracy and ease of publishing trials by col-
laborating with other major journal publishers and the US
National Institutes of Health to create standard electronic
templates for submission and publication of trials.
Analysis and discussion
In addition to publishing original data and analysis of con-
trolled clinical trials, we plan to publish abstracts, brief
commentaries, reviews, and reports highlighting recent
clinical trials and important developments in cardiovascu-
lar medicine wherever they appear in the world’s literature,
and to include articles that debate controversial topics.
We will also be setting up online discussion forums on a
range of topics relevant to cardiovascular medicine, and
providing links to other relevant databases, such as
PubMed (http://www.ncbi.nlm.nih.gov/PubMed), PubMed
Central (http://pubmedcentral.nih.gov), and Cardiosource
(http://cardiosource.com).
We hope that you will enjoy this first issue of Current
Controlled Trials in Cardiovascular Medicine, and that
you will begin to make the journal your own, by sending us
your work, initiating and contributing to debates, and com-
menting on published articles. We look forward to your
comments and suggestions on how we can work with you
to improve the design and implementation of clinical trials
in cardiovascular medicine, and the interpretation and
application of their results.
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